Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment

首页> 外文期刊>Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer >Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment

【24h】

Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment

机译：本地化MSI / DMMR胃癌患者，围手术期免疫疗法而不是化疗：甘氏甘油龙蜥Neanipiga II研究将打开招聘

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction > Perioperative chemotherapy is the standard strategy for localized gastric cancers. Nevertheless, this strategy seems to be inefficient, if not deleterious, for patients with tumors harboring microsotellite instability (MSI) and/or mismatch repair deficiency (dMMR), a tumor phenotype predictive for the efficacy of immune checkpoint inhibitors (ICKi).

机译：介绍>围手术期化疗是局部胃癌的标准策略。尽管如此，对于患有微透明石不稳定性（MSI）和/或不匹配的修复缺陷（DMMR）的肿瘤患者，这种策略似乎是低效的，如果不歧视肿瘤患者，肿瘤表型对免疫检查点抑制剂（ICHI）的疗效预测性。

著录项

来源
《Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer》 |2020年第4期|共9页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 fre
中图分类肿瘤学;
关键词
Gastric cancer; Microsatellite instability; Lynch syndrome; Nivolumab; Ipilimumab;

机译：胃癌;微卫星不稳定性;林奇综合征;Nivolumab;Ipilimumab;

相似文献

外文文献
专利

1. Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment [J] . Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer . 2020,第4期

机译：本地化MSI / DMMR胃癌患者，围手术期免疫疗法而不是化疗：甘氏甘油龙蜥Neanipiga II研究将打开招聘
2. Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST) (vol 107, pg 46, 2019) [J] . Watson S., de la Fouchardiere C., Kim S., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：奥沙利铂，5-氟尿嘧啶和Nab-PACLITAXEL作为可重置胃腺癌患者的围手术期方案：戈尔植物II研究（Foxagast）（Vol 107，PG 46,2019）
3. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [J] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, BMC Cancer . 2019,第1期

机译：EORTC-1203-GITCG-“创新”试验：单纯化疗与化疗加曲妥珠单抗相比，与化疗加曲妥珠单抗加培妥珠单抗在围手术期治疗HER2阳性，胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组，韩国癌症研究组和荷兰上消化道癌组的II组间试验
4. Effects of Weekly Paclitaxel as a Second-Iine Anticancer Chemotherapy for Patients with Advanced and Recurrent Gastric Carcinoma [C] . Y. Sakurai, I. Yoshida, T. Masui, International Gastric Cancer Congress . 2005

机译：每周紫杉醇作为先进和复发性胃癌患者的二缘抗癌化疗的影响
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. EORTC-1203-GITCG - the INNOVATION-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus pertuzumab in the perioperative treatment of HER2 positive gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG-创新试验：单纯化疗与化疗加曲妥珠单抗相比与化疗加曲妥珠单抗加帕妥珠单抗在围手术期治疗HER2阳性胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组韩国癌症研究组和荷兰上消化道癌组的II组间试验
7. Erratum to ‘Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)’ Eur J Cancer 107 (January 2019) 46–52 [O] . S. Watson, C. de la Fouchardière, S. Kim, 2019

机译：错误到'Oxaliplatin，5-氟尿嘧啶和Nab-κBab-κBab-paclitaxel作为可重症胃腺癌患者的围手术期方案：戈尔戈尔期II研究（Foxagast）'eur J Cancer 107（2019年1月）46-52

Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment

摘要

著录项

相似文献

相关主题

期刊订阅